Ge Long Hui·2025-09-04 10:08Core Viewpoint - Shanghai Pharmaceuticals has received approval for its Dihydroxypropyl Theophylline Injection from the National Medical Products Administration, indicating successful consistency evaluation for generic drug quality and efficacy [1] Group 1: Company Developments - Shanghai Pharmaceuticals' subsidiary, Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd., has been granted a Supplementary Application Approval Notice for Dihydroxypropyl Theophylline Injection [1] - The drug is indicated for bronchial asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and symptoms of dyspnea due to cardiogenic pulmonary edema [1] - The company has invested approximately RMB 3.05 million in research and development for this drug as of the announcement date [1] Group 2: Market Insights - According to IQVIA data, the procurement amount for Dihydroxypropyl Theophylline Injection (2ml: 0.3g) in hospitals across mainland China for 2024 is RMB 9.737 million [2] - Major domestic manufacturers of this drug include Jilin Jingsheng Pharmaceutical Co., Shanxi Taiyuan Pharmaceutical Co., and Suicheng Pharmaceutical Co., Ltd. [1]